Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 6/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.61 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.61 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.61 |
| ▸ | BRD4 | O60885 | 5/20 | 0.59 |
| ▸ | BRD2 | P25440 | 2/20 | 0.59 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.59 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7519416 | 0.90 | PDE4A (0.56) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL836619 | 0.87 | MEN1 (0.77) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL11462282 | 0.87 | PDE4A (0.64) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL1713301 | 0.86 | MEN1 (0.71) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL516463 | 0.86 | PDE4A (0.81) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL11460096 | 0.85 | MEN1 (0.65) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL9010501 | 0.83 | ADORA2B (0.62) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL7464482 | 0.82 | PDE4A (0.86) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL11367607 | 0.81 | MEN1 (0.50) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL7031729 | 0.80 | MEN1 (0.87) | PDE4AADORA2APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034143-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, LLC (US) | 2025-01-30 | — | — | US | disclosed |
| US-11958854-B2 | Substituted xanthines and methods of use thereof | HYDRA BIOSCIENCES, LLC (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230040259-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, LLC (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230040259-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, LLC (US) | 2023-02-09 | — | — | US | disclosed |
| US-11208409-B2 | Substituted xanthines and methods of use thereof | HYDRA BIOSCIENCES, LLC (US) | 2021-12-28 | — | — | US | disclosed |
| US-11208409-B2 | Substituted xanthines and methods of use thereof | HYDRA BIOSCIENCES, LLC (US) | 2021-12-28 | — | — | US | disclosed |
| CN-107082782-B | Substituted xanthines and methods of use thereof | 海德拉生物科学有限责任公司 | 2020-03-20 | — | — | CN | disclosed |
| US-20190322667-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-10-24 | — | — | US | disclosed |
| US-20190322667-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-10-24 | — | — | US | disclosed |
| US-10399982-B2 | Substituted xanthines and methods of use thereof | HYDRA BIOSCIENCES, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| EP-2970303-A2 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | Hydra Biosciences, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014143799-A9 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014143799-A9 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014143799-A2 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275071-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275071-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275071-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| EP-0413278-B1 | Use of xanthine derivatives against peptic ulcers | HOECHST JAPAN (JP) | 1996-11-06 | — | — | EP | disclosed |
| US-5109003-A | METHOD FOR THE TREATMENT OF PEPTIC ULCER DISEASE | HOECHST JAPAN LIMITED (JP) | 1992-04-28 | — | — | US | disclosed |
| EP-0413278-A2 | Use of xanthine derivatives against peptic ulcers | HOECHST JAPAN LIMITED (JP) | 1991-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11958854-B2 | Substituted xanthines and methods of use thereof | TRPC5, TRPC7, TRPC4 | PDE4A 615/4885ADORA2A 486/4885PDE4B 583/4885 |
| US-20230040259-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | PDE4A 615/4885ADORA2A 486/4885PDE4B 583/4885 |
| US-20250034143-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | PDE4A 615/4885ADORA2A 486/4885PDE4B 583/4885 |
| US-20140275071-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | PDE4A 615/4885ADORA2A 486/4885PDE4B 583/4885 |
| US-10399982-B2 | Substituted xanthines and methods of use thereof | TRPC5, TRPC7, TRPC4 | PDE4A 615/4885ADORA2A 486/4885PDE4B 583/4885 |
| US-11208409-B2 | Substituted xanthines and methods of use thereof | TRPC5, TRPC7, TRPC4 | PDE4A 615/4885ADORA2A 486/4885PDE4B 583/4885 |
| US-20190322667-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | PDE4A 615/4885ADORA2A 486/4885PDE4B 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.